Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | The impact of belumosudil in patients with chronic GvHD

Rebecca Gonzalez • 16 Feb 2023
Tandem Meetings 2023
General Belumosudil Ruxolitinib

Rebecca Gonzalez, PharmD, BCOP, Moffitt Cancer Center, Tampa, FL, highlights the benefits of belumosudil in patients with chronic graft-versus-host disease (cGvHD), commenting on its safety profile and its activity in patients with fibrotic, sclerotic, and lung cGvHD, and in patients who have received prior lines of therapy. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rebecca Gonzalez

4:50
Impact of belumosudil on tacrolimus & sirolimus pharmacokinetics in patients with chronic GvHD
Rebecca Gonzalez • 16 Feb 2023
3:36
Latest advances in GvHD prophylaxis: TAC/MMF/PTCy & abatacept
Rebecca Gonzalez • 16 Feb 2023
2:33
Evolution & goals of GvHD prophylaxis strategies
Rebecca Gonzalez • 16 Feb 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals